|Mr. John M. Holliman III||Exec. Chairman & CEO||51k||N/A||63|
|Mr. Leslie M. Taeger||Sr. VP, CFO and Principal Financial & Accounting Officer||79k||N/A||66|
|Dr. Randolph C. Steer M.D., Ph.D.||Chief Medical Officer & Consultant||4k||N/A||67|
|Dr. William M. Wardell M.D., Ph.D.||Head of Clinical & Regulatory Review Board||N/A||N/A||78|
|Ms. Karen Struck||Investor Relations Professional||N/A||N/A||N/A|
Capstone Therapeutics Corp., a biotechnology company, develops and sells novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have been completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Capstone Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.